MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejmech.2026.118667

Медицинская библиотека · European journal of medicinal chemistry · 2026

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia.

Wei Qingyun, Zhang Jian, Chen Jiao, Cai Xueting, Zhou Jinpei, Wang Bo, Zhang Huibin, Cao Peng

СтатьяПеревод в очереди

Аннотация

Targeting bromodomain and extra-terminal (BET) proteins is a promising therapeutic strategy for acute myeloid leukemia (AML). However, clinical development of conventional BET inhibitors has been limited by dose-related toxicities and compensatory resistance. Proteolysis-targeting chimeras (PROTACs) offer a catalytic and often more selective alternative by degrading target proteins via the ubiquitin-proteasome system. In this work, we designed and synthesized a series of novel BET PROTACs based on the clinical inhibitor ABBV-075. Through systematic optimization of linker length/composition and E3 ligase ligands (CRBN or VHL), we identified two highly potent PROTACs, A10 (CRBN-based) and A12 (VHL-based). Both compounds effectively degraded BET proteins, inhibited cell proliferation, induced cell-cycle arrest, and promoted apoptosis in MV4-11 AML cells. In MV4-11 xenograft models, A10 (6 mg/kg) and A12 (2 mg/kg) demonstrated significant tumor growth inhibition (76.2% and 60.5%, respectively). A comprehensive drug-likeness assessment revealed that while A12 exhibited higher systemic exposure in pharmacokinetic studies, A10 displayed a markedly superior safety profile with minimal hepatorenal toxicity. The favorable efficacy-safety balance of A10 underscores its strong potential as a preclinical candidate for AML therapy. This study highlights how rational PROTAC optimization can yield degraders with enhanced therapeutic windows, providing a promising path forward for targeted protein degradation in AML.

Для цитирования: Wei Qingyun, Zhang Jian, Chen Jiao, Cai Xueting, Zhou Jinpei, Wang Bo, Zhang Huibin, Cao Peng. Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia.. European journal of medicinal chemistry. 2026. DOI: 10.1016/j.ejmech.2026.118667.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.